Cholesterol Metabolism

0.0(0)
studied byStudied by 0 people
0.0(0)
full-widthCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/9

encourage image

There's no tags or description

Looks like no tags are added yet.

Study Analytics
Name
Mastery
Learn
Test
Matching
Spaced

No study sessions yet.

10 Terms

1
New cards

Structure of cholesterol

  • 3 fursed hex rings and 1 pent ring

  • sterol → OH on thrid carbon of A ring

  • FA is added to chol in ER → less polor and more hydrophobic - better for travel

<ul><li><p>3 fursed hex rings and 1 pent ring</p></li><li><p>sterol → OH on thrid carbon of A ring</p></li><li><p>FA is added to chol in ER → less polor and more hydrophobic - better for travel</p></li></ul><p></p>
2
New cards

Overveiw of cholesterols function

  • regulates membrane fluidity as cell membrane component

  • precursor of hormones (test and est), bile acid, and vitamin D

  • be used for bile synthesis

  • main source of cholesterol is through synthesis, not diet

  • all nucleated cells can synthesize cholesterol from acetyl CoA through the Mevalonate pathway

    • however, main synthesis organs are the liver, intestine, adrenal cortex, ovaries, testes, and placenta

3
New cards

First stage of cholesterol synthesis

  • occurs in cytosol

  • 3 acetyl CoAs are condensed to geterate 1 HMG-CoA

  • HMG-CoA can be converted into mevalonate acid

    • irreversible and rate limiting step

4
New cards

Cholesterol converted to hormones

  • occurs in mitochondira

  • makes aldosterone, cortisol, testosterone, and estradiol

5
New cards

Cholesterol → bile acid synthesis

Bile/bile salts released from liver

go into gut/intestine and converted into bile acid

6
New cards

Cholesterol transport pathway

  • dietary cholesterol packed into CM (released from intestine)

  • Dietary cholesterol and TAG packed into VLDL and released from liver

  • LDL is taken into cells through endocytosis and cholesterol is released

  • excess cholesterol delivered to HDL

    • reverse cholesterol transport back to liver

    • liver will bake bile or new VLDLs

<ul><li><p>dietary cholesterol packed into CM (released from intestine)</p></li><li><p>Dietary cholesterol and TAG packed into VLDL and released from liver</p></li><li><p>LDL is taken into cells through endocytosis and cholesterol is released</p></li><li><p>excess cholesterol delivered to HDL</p><ul><li><p>reverse cholesterol transport back to liver</p></li><li><p>liver will bake bile or new VLDLs</p></li></ul></li></ul><p></p>
7
New cards

Regulation of cholesterol in first pathway

  • negative feedback control by HMG-CoA reductase in Mevalonate synthesis

  • inhibited by high levels of cholesterol (rate limited step)

8
New cards

Control biosynthesis of cholesterol by SREBP

  • high levels of cholesterol → blocks SREBP from translocating from ER to Golgi → cholesterol synthesis is inhibited

  • Low levels of cholesterol → SREBP is located at the ER by SCAP. SCAP holds SREBP into ER

    • SCAP then releases SREBP, SREBP is transported to golgi via COPII transport system

    • in golgi, 2 proteases cleave SREBP resulting in release of SREBP (active transcription factor)

    • SREBP moves to nucleus and initates transcription of target genes like HMG-CoaAR

9
New cards

Regulation: protosomal degradation of HMG-CoA reductase

  • high level of cholesterol

  • binding/inhibition of HMG CoA accelerates

  • degradation of HMG CoA reductase through proteasome degradation pathway

    • inhibits cholesterol synthesis

10
New cards

Lower cholesterol level through drugs (3)

  1. inhibition of cholesterol synthesis statin

    1. competatively inhibits HMG-CoA reductase

  2. inhibition of cholesterol absorption

    1. Ezetimbe- inhibitor of NPC1, major regulator of cholesterol absorption → lowering plasma cholesterol level

    2. often used with statin together

  3. increase LDL clearance - best

    1. PSCK9 secreted from the kidneys, livier, and intestine

    2. binds to LDLR, results in degradation of LDLR receptor

    3. PCSK-9 inhibitor decreased LDLR degradation results in increased LDLR receptor level, therefore more LDLR bound LDLs are endocytosed by liver cells which reduces plasma level of LDL